COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026

COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Coronavirus Disease 2019 (Covid-19): Postmenopausal Vaginal Atrophy Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Postmenopausal Vaginal Atrophy Drugs Industry
1.6.1.1 Postmenopausal Vaginal Atrophy Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Postmenopausal Vaginal Atrophy Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
2.2 Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2020 Versus 2026
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players
3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description, Business Overview and Total Revenue
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Recent Development
11.2 Bionovo, Inc.
11.2.1 Bionovo, Inc. Corporation Information
11.2.2 Bionovo, Inc. Description, Business Overview and Total Revenue
11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.2.5 Bionovo, Inc. Recent Development
11.3 Endoceutics, Inc.
11.3.1 Endoceutics, Inc. Corporation Information
11.3.2 Endoceutics, Inc. Description, Business Overview and Total Revenue
11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.3.5 Endoceutics, Inc. Recent Development
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Corporation Information
11.4.2 Novo Nordisk A/S Description, Business Overview and Total Revenue
11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
11.4.5 Novo Nordisk A/S Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Corporation Information
11.5.2 Pfizer Inc. Description, Business Overview and Total Revenue
11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.5.5 Pfizer Inc. Recent Development
11.6 Teva Pharmaceuticals Ltd.
11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
11.6.2 Teva Pharmaceuticals Ltd. Description, Business Overview and Total Revenue
11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.6.5 Teva Pharmaceuticals Ltd. Recent Development
11.7 Therapeutics MD, Inc.
11.7.1 Therapeutics MD, Inc. Corporation Information
11.7.2 Therapeutics MD, Inc. Description, Business Overview and Total Revenue
11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.7.5 Therapeutics MD, Inc. Recent Development
11.8 Shionogi & Company
11.8.1 Shionogi & Company Corporation Information
11.8.2 Shionogi & Company Description, Business Overview and Total Revenue
11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
11.8.5 Shionogi & Company Recent Development
11.9 Allergan plc
11.9.1 Allergan plc Corporation Information
11.9.2 Allergan plc Description, Business Overview and Total Revenue
11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.9.5 Allergan plc Recent Development
11.10 Shionogi & Co. Ltd.
11.10.1 Shionogi & Co. Ltd. Corporation Information
11.10.2 Shionogi & Co. Ltd. Description, Business Overview and Total Revenue
11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.10.5 Shionogi & Co. Ltd. Recent Development
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description, Business Overview and Total Revenue
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Recent Development
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
List of Tables
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Segments
Table 2. Ranking of Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Premarin
Table 5. Major Manufacturers of Vagifem
Table 6. Major Manufacturers of Estrace
Table 7. Major Manufacturers of Estring
Table 8. Major Manufacturers of Femring
Table 9. COVID-19 Impact Global Market: (Four Postmenopausal Vaginal Atrophy Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Postmenopausal Vaginal Atrophy Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2015-2020 (K Units)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions (2015-2020)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers (2015-2020)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2019)
Table 23. Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2015-2020) (USD/Unit)
Table 26. Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 28. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2015-2020)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2015-2020)
Table 34. Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2015-2020)
Table 37. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 38. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 39. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 41. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 42. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 43. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 44. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 47. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 49. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 51. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 60. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 61. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 62. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 65. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 66. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 67. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 68. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 76. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 77. Actavis plc Corporation Information
Table 78. Actavis plc Description and Major Businesses
Table 79. Actavis plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Actavis plc Product
Table 81. Actavis plc Recent Development
Table 82. Bionovo, Inc. Corporation Information
Table 83. Bionovo, Inc. Description and Major Businesses
Table 84. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Bionovo, Inc. Product
Table 86. Bionovo, Inc. Recent Development
Table 87. Endoceutics, Inc. Corporation Information
Table 88. Endoceutics, Inc. Description and Major Businesses
Table 89. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Endoceutics, Inc. Product
Table 91. Endoceutics, Inc. Recent Development
Table 92. Novo Nordisk A/S Corporation Information
Table 93. Novo Nordisk A/S Description and Major Businesses
Table 94. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Novo Nordisk A/S Product
Table 96. Novo Nordisk A/S Recent Development
Table 97. Pfizer Inc. Corporation Information
Table 98. Pfizer Inc. Description and Major Businesses
Table 99. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Pfizer Inc. Product
Table 101. Pfizer Inc. Recent Development
Table 102. Teva Pharmaceuticals Ltd. Corporation Information
Table 103. Teva Pharmaceuticals Ltd. Description and Major Businesses
Table 104. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Teva Pharmaceuticals Ltd. Product
Table 106. Teva Pharmaceuticals Ltd. Recent Development
Table 107. Therapeutics MD, Inc. Corporation Information
Table 108. Therapeutics MD, Inc. Description and Major Businesses
Table 109. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Therapeutics MD, Inc. Product
Table 111. Therapeutics MD, Inc. Recent Development
Table 112. Shionogi & Company Corporation Information
Table 113. Shionogi & Company Description and Major Businesses
Table 114. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Shionogi & Company Product
Table 116. Shionogi & Company Recent Development
Table 117. Allergan plc Corporation Information
Table 118. Allergan plc Description and Major Businesses
Table 119. Allergan plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Allergan plc Product
Table 121. Allergan plc Recent Development
Table 122. Shionogi & Co. Ltd. Corporation Information
Table 123. Shionogi & Co. Ltd. Description and Major Businesses
Table 124. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Shionogi & Co. Ltd. Product
Table 126. Shionogi & Co. Ltd. Recent Development
Table 127. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 128. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 129. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 130. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 131. North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 132. North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 136. Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 137. Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 138. Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 140. Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 142. Key Challenges
Table 143. Market Risks
Table 144. Main Points Interviewed from Key Postmenopausal Vaginal Atrophy Drugs Players
Table 145. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 146. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Premarin Product Picture
Figure 4. Vagifem Product Picture
Figure 5. Estrace Product Picture
Figure 6. Estring Product Picture
Figure 7. Femring Product Picture
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Vaginal Gels
Figure 10. Creams
Figure 11. Tablets
Figure 12. Rings
Figure 13. Patches
Figure 14. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2015-2026 (US$ Million)
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026 (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
Figure 24. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2015-2020)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type in 2019
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Range (2015-2020)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2015-2020)
Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application in 2019
Figure 34. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 35. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 37. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 38. U.S. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 39. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 41. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 44. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 45. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 48. Germany Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 55. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 57. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 59. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 60. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 61. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 63. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 64. China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth R

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs